X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (3799) 3799
niacinamide - analogs & derivatives (3044) 3044
male (2076) 2076
antineoplastic agents - therapeutic use (1863) 1863
female (1806) 1806
phenylurea compounds - therapeutic use (1731) 1731
oncology (1708) 1708
sorafenib (1667) 1667
middle aged (1473) 1473
phenylurea compounds (1415) 1415
aged (1273) 1273
pyridines - therapeutic use (1227) 1227
cancer (1115) 1115
niacinamide - therapeutic use (1107) 1107
treatment outcome (1074) 1074
animals (1045) 1045
liver neoplasms - drug therapy (1027) 1027
carcinoma, hepatocellular - drug therapy (974) 974
benzenesulfonates - therapeutic use (971) 971
adult (929) 929
protein kinase inhibitors - therapeutic use (846) 846
phenylurea compounds - pharmacology (807) 807
phenylurea compounds - administration & dosage (663) 663
carcinoma, renal cell - drug therapy (659) 659
kidney neoplasms - drug therapy (653) 653
hepatocellular carcinoma (644) 644
care and treatment (612) 612
antineoplastic agents - adverse effects (600) 600
phenylurea compounds - adverse effects (593) 593
liver neoplasms - pathology (592) 592
antineoplastic agents (568) 568
mice (561) 561
carcinoma, hepatocellular - pathology (549) 549
cell line, tumor (549) 549
antimitotic agents (544) 544
antineoplastic combined chemotherapy protocols - therapeutic use (530) 530
pharmacology & pharmacy (522) 522
aged, 80 and over (496) 496
antineoplastic agents - pharmacology (476) 476
chemotherapy (475) 475
survival (465) 465
liver cancer (464) 464
sunitinib (454) 454
disease-free survival (445) 445
niacinamide - administration & dosage (445) 445
angiogenesis (438) 438
pyridines - adverse effects (438) 438
metastasis (431) 431
therapy (424) 424
indoles - therapeutic use (423) 423
prognosis (419) 419
retrospective studies (407) 407
pyrroles - therapeutic use (402) 402
tumors (395) 395
expression (388) 388
pyridines - administration & dosage (386) 386
bevacizumab (385) 385
gastroenterology & hepatology (378) 378
hepatoma (376) 376
medicine & public health (375) 375
analysis (369) 369
kidney neoplasms - pathology (369) 369
niacinamide - adverse effects (368) 368
apoptosis (365) 365
drug therapy (359) 359
antineoplastic agents - administration & dosage (355) 355
niacinamide - pharmacology (353) 353
research (352) 352
benzenesulfonates - adverse effects (339) 339
pyridines - pharmacology (334) 334
endothelial growth-factor (333) 333
protein kinase inhibitors - adverse effects (331) 331
neoplasm staging (317) 317
protein kinase inhibitors - pharmacology (308) 308
digestive system diseases (302) 302
cell proliferation - drug effects (300) 300
benzenesulfonates - administration & dosage (298) 298
efficacy (289) 289
disease progression (288) 288
vascular endothelial growth factor (288) 288
carcinoma, hepatocellular - therapy (287) 287
angiogenesis inhibitors - therapeutic use (284) 284
liver neoplasms - therapy (284) 284
neoplasms (279) 279
apoptosis - drug effects (273) 273
liver neoplasms - mortality (269) 269
carcinoma, hepatocellular - mortality (267) 267
kinases (266) 266
dose-response relationship, drug (259) 259
survival rate (257) 257
neoplasm metastasis (253) 253
safety (250) 250
trial (250) 250
cancer therapies (248) 248
carcinoma (247) 247
antitumor-activity (245) 245
clinical trials (241) 241
hematology, oncology and palliative medicine (240) 240
kaplan-meier estimate (239) 239
neoplasms - drug therapy (235) 235
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (3983) 3983
Japanese (102) 102
French (50) 50
German (45) 45
Chinese (40) 40
Spanish (20) 20
Hungarian (9) 9
Dutch (5) 5
Czech (4) 4
Italian (4) 4
Portuguese (2) 2
Korean (1) 1
Russian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


European urology, ISSN 0302-2838, 2017, Volume 71, Issue 3, pp. 426 - 436
...), the most effective therapeutic approach for patients with non-clear cell RCC (non-ccRCC) is unknown. Objective To systematically review relevant literature comparing... 
Urology | Papillary | Systematic review | Sunitinib | Non-clear cell renal cell carcinoma | Everolimus | Chromophobe | carcinoma | Review | Non-clear cell renal cell | Journal Article | UROLOGY & NEPHROLOGY | PHASE-II | Niacinamide - analogs & derivatives | Anilides - therapeutic use | Bevacizumab - therapeutic use | Humans | Interleukin-2 - therapeutic use | Antineoplastic Agents - therapeutic use | Interferons - therapeutic use | Comparative Effectiveness Research | Quinolones - therapeutic use | Everolimus - therapeutic use | Imidazoles - therapeutic use | Carcinoma, Renal Cell - drug therapy | Pyrroles - therapeutic use | Benzimidazoles - therapeutic use | Pyridines - therapeutic use | Sirolimus - analogs & derivatives | Sirolimus - therapeutic use | Carcinoma, Renal Cell - pathology | Pyrrolidinones - therapeutic use | Niacinamide - therapeutic use | Phenylurea Compounds - therapeutic use | Disease-Free Survival | Sulfonamides - therapeutic use | Pyrimidines - therapeutic use | Indoles - therapeutic use | Kidney Neoplasms - pathology | Erlotinib Hydrochloride - therapeutic use | Quinolines - therapeutic use | Kidney Neoplasms - drug therapy | Indazoles - therapeutic use | Medical colleges | Care and treatment | Carcinoma, Renal cell | Endothelial growth factors | Analysis | Endothelium | Urologi och njurmedicin | Medical and Health Sciences | Medicin och hälsovetenskap | Klinisk medicin | Clinical Medicine | Cancer and Oncology | Urology and Nephrology | Cancer och onkologi
Journal Article
European journal of cancer (1990), ISSN 0959-8049, 2013, Volume 49, Issue 16, pp. 3412 - 3419
Abstract Purpose We assessed the safety of the multikinase inhibitor regorafenib in patients with hepatocellular carcinoma (HCC) that had progressed following... 
Hematology, Oncology and Palliative Medicine | Second line | Regorafenib | Hepatocellular carcinoma | Tolerability | Safety | Receptor kinase inhibition | Safety Second line | MANAGEMENT | EFFICACY | ONCOLOGY | SUNITINIB | Carcinoma, Hepatocellular - mortality | Humans | Middle Aged | Pyridines - pharmacokinetics | Male | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Protein Kinase Inhibitors - adverse effects | Liver Neoplasms - mortality | Pyridines - adverse effects | Carcinoma, Hepatocellular - drug therapy | Time Factors | Antineoplastic Agents - adverse effects | Phenylurea Compounds - adverse effects | Adult | Female | Liver Neoplasms - pathology | Antineoplastic Agents - pharmacokinetics | Phenylurea Compounds - pharmacokinetics | Liver Neoplasms - enzymology | Pyridines - therapeutic use | Protein Kinase Inhibitors - pharmacokinetics | Pyridines - administration & dosage | Drug Administration Schedule | Europe | Kaplan-Meier Estimate | Liver Neoplasms - drug therapy | Phenylurea Compounds - therapeutic use | Treatment Outcome | Carcinoma, Hepatocellular - enzymology | Disease Progression | Protein Kinase Inhibitors - administration & dosage | Phenylurea Compounds - administration & dosage | Asia | Protein Kinase Inhibitors - therapeutic use | Carcinoma, Hepatocellular - pathology | Aged | Neoplasm Staging | Care and treatment | Safety and security measures | Hepatoma | Index Medicus
Journal Article
Cochrane library, ISSN 1465-1858, 2012, Volume 2020, Issue 7, p. CD008943
Background Pharmacotherapy remains an important modality for the treatment of neuropathic pain. However, as monotherapy current drugs are associated with... 
gamma-Aminobutyric Acid | Nortriptyline | Amines | Chronic non-cancer pain | Gabapentin | Morphine | Phenylurea Compounds | Pregabalin | Pain & anaesthesia | Management | 2019 3. Chronic pain | 2019 3.1 Neuropathic pain | Analgesics | Acetaminophen | Antidepressive Agents, Tricyclic | Thioctic Acid | Tramadol | Benzodiazepinones | Cyclohexanecarboxylic Acids | N-Methylaspartate | Neuralgia | Pharmacological therapies | Drug Therapy, Combination | Medicine General & Introductory Medical Sciences | MEDICINE, GENERAL & INTERNAL | POSTHERPETIC NEURALGIA | DIABETIC PERIPHERAL NEUROPATHY | SPINAL-CORD-INJURY | CANCER PAIN | RANDOMIZED CONTROLLED-TRIAL | PLACEBO-CONTROLLED TRIAL | QUALITY-OF-LIFE | DOUBLE-BLIND CROSSOVER | LIDOCAINE MEDICATED PLASTER | CHRONIC NONCANCER PAIN | Analgesics - therapeutic use | Cyclohexanecarboxylic Acids - therapeutic use | Humans | Phenylurea Compounds - therapeutic use | N-Methylaspartate - antagonists & inhibitors | Neuralgia - drug therapy | Nortriptyline - therapeutic use | Tramadol - therapeutic use | Drug Therapy, Combination - methods | Antidepressive Agents, Tricyclic - therapeutic use | Amines - therapeutic use | Adult | gamma-Aminobutyric Acid - therapeutic use | Acetaminophen - therapeutic use | gamma-Aminobutyric Acid - analogs & derivatives | Benzodiazepinones - therapeutic use | Morphine - therapeutic use | Thioctic Acid - therapeutic use
Journal Article
Nature (London), ISSN 0028-0836, 2016, Volume 538, Issue 7625, pp. 344 - 349
Antimalarial drugs have thus far been chiefly derived from two sources-natural products and synthetic drug-like compounds... 
IN-VITRO | TRANSFER-RNA SYNTHETASE | MALARIA CONTROL | PLASMODIUM-FALCIPARUM | MULTIDISCIPLINARY SCIENCES | DRUG DISCOVERY | LIVER | TARGETS | PROTEIN-SYNTHESIS | NEXT-GENERATION | HEPATIC STAGES | Azabicyclo Compounds - pharmacology | Plasmodium falciparum - enzymology | Malaria, Falciparum - prevention & control | Male | Plasmodium falciparum - cytology | Azetidines - pharmacology | Plasmodium falciparum - drug effects | Cytosol - enzymology | Malaria, Falciparum - transmission | Liver - drug effects | Azabicyclo Compounds - chemical synthesis | Azabicyclo Compounds - therapeutic use | Female | Safety | Antimalarials - chemical synthesis | Disease Models, Animal | Life Cycle Stages - drug effects | Malaria, Falciparum - drug therapy | Azabicyclo Compounds - administration & dosage | Azetidines - adverse effects | Phenylurea Compounds - therapeutic use | Antimalarials - therapeutic use | Macaca mulatta - parasitology | Phenylalanine-tRNA Ligase - antagonists & inhibitors | Drug Discovery | Antimalarials - pharmacology | Animals | Azetidines - administration & dosage | Phenylurea Compounds - chemical synthesis | Antimalarials - administration & dosage | Azetidines - therapeutic use | Phenylurea Compounds - administration & dosage | Mice | Phenylurea Compounds - pharmacology | Liver - parasitology | Plasmodium falciparum - growth & development | Prevention | Antimalarials | Disease transmission | Health aspects | Transfer RNA | Proteins | Cytochrome | Malaria | Liver | Parasites | Kinases | Drug resistance | Drug dosages
Journal Article
Cancer treatment reviews, ISSN 0305-7372, 2016, Volume 50, pp. 109 - 117
... are approved for first-line or later-line use in the treatment of patients with mRCC [1–3] . Among these agents, 1 is a monoclonal antibody targeting vascular endothelial... 
Hematology, Oncology and Palliative Medicine | Prognostic markers | Predictive markers | Sequential therapy | Overall survival | Targeted therapy | mRCC | PROGRESSION-FREE SURVIVAL | 1ST-LINE SUNITINIB | BLIND PHASE-III | OPEN-LABEL | INTERFERON-ALPHA | ONCOLOGY | 2ND-LINE TREATMENT | EXPRESSION LEVELS | CANCER-SPECIFIC SURVIVAL | CLINICAL-PRACTICE | DOSE TITRATION | Niacinamide - analogs & derivatives | Anilides - therapeutic use | Kidney Neoplasms - genetics | Bevacizumab - therapeutic use | Prognosis | Humans | Gene Expression Regulation, Neoplastic | Carcinoma, Renal Cell - genetics | Antibodies, Monoclonal - therapeutic use | Antineoplastic Agents - therapeutic use | Kidney Neoplasms - metabolism | Vascular Endothelial Growth Factor A - genetics | Sunitinib | Tumor Suppressor Proteins - genetics | Biomarkers, Tumor - metabolism | Axitinib | Everolimus - therapeutic use | Von Hippel-Lindau Tumor Suppressor Protein - genetics | Imidazoles - therapeutic use | Carcinoma, Renal Cell - drug therapy | Nuclear Proteins - genetics | Pyrroles - therapeutic use | Molecular Targeted Therapy - methods | Pyridines - therapeutic use | Histone-Lysine N-Methyltransferase - genetics | Sirolimus - analogs & derivatives | Sirolimus - therapeutic use | Receptors, CCR4 - genetics | Interferon-alpha - therapeutic use | Niacinamide - therapeutic use | Phenylurea Compounds - therapeutic use | Transcription Factors - genetics | Ubiquitin Thiolesterase - genetics | Carcinoma, Renal Cell - metabolism | Sulfonamides - therapeutic use | Pyrimidines - therapeutic use | Carcinoma, Renal Cell - secondary | Nivolumab | Sorafenib | Indoles - therapeutic use | Kidney Neoplasms - pathology | MicroRNAs - genetics | Quinolines - therapeutic use | Mutation | Kidney Neoplasms - drug therapy | Indazoles - therapeutic use | Precision Medicine - methods | Immunologic Factors - therapeutic use | Antimitotic agents | Care and treatment | Metastasis | Antineoplastic agents | Patient outcomes | Cancer
Journal Article
The lancet oncology, ISSN 1470-2045, 2015, Volume 16, Issue 16, pp. 1691 - 1699
Summary Background Preclinical data and results from non-randomised trials suggest that the multikinase inhibitor sorafenib might be an effective drug for the... 
Hematology, Oncology and Palliative Medicine | AML | ONCOLOGY | ACUTE MYELOGENOUS LEUKEMIA | BONE-MARROW | CLASSIFICATION | FLT3 MUTATIONS | CYTARABINE | STEM-CELL TRANSPLANTATION | COMBINATION | ELDERLY-PATIENTS | CHEMOTHERAPY | Niacinamide - analogs & derivatives | Recurrence | Age Factors | Cytarabine - therapeutic use | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Protein Kinase Inhibitors - adverse effects | Transplantation, Homologous | Neoadjuvant Therapy - mortality | Time Factors | Phenylurea Compounds - adverse effects | Leukemia, Myeloid, Acute - drug therapy | Adult | Female | Chemotherapy, Adjuvant | Daunorubicin - therapeutic use | Double-Blind Method | Risk Factors | Kaplan-Meier Estimate | Niacinamide - adverse effects | Proportional Hazards Models | Hematopoietic Stem Cell Transplantation | Niacinamide - therapeutic use | Phenylurea Compounds - therapeutic use | Treatment Outcome | Disease Progression | Leukemia, Myeloid, Acute - mortality | Disease-Free Survival | Antimetabolites, Antineoplastic - therapeutic use | Leukemia, Myeloid, Acute - diagnosis | Antibiotics, Antineoplastic - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Neoadjuvant Therapy - adverse effects | Protein Kinase Inhibitors - therapeutic use | Germany | Antimitotic agents | Clinical trials | Chemotherapy | Antineoplastic agents | Standards | Cancer
Journal Article
The Lancet (British edition), ISSN 0140-6736, 2016, Volume 388, Issue 10043, pp. 518 - 529
...) pathway inhibitors into the therapeutic armoury. Although some tumours such as renal cell carcinoma, ovarian and cervical cancers, and pancreatic neuroendocrine... 
Internal Medicine | PHASE-III TRIAL | ADVANCED HEPATOCELLULAR-CARCINOMA | BREAST-CANCER | MEDICINE, GENERAL & INTERNAL | PANCREATIC NEUROENDOCRINE TUMORS | TYROSINE KINASE INHIBITOR | RECURRENT OVARIAN-CANCER | ANTI-ANGIOGENIC THERAPY | RESISTANT PROSTATE-CANCER | METASTATIC COLORECTAL-CANCER | RENAL-CELL CARCINOMA | Neoplasms - metabolism | Niacinamide - analogs & derivatives | Humans | Drug Resistance, Neoplasm | Vascular Endothelial Growth Factor A - metabolism | Vascular Endothelial Growth Factor A - antagonists & inhibitors | Angiogenesis Inhibitors - therapeutic use | Biomarkers, Tumor - metabolism | Female | Neovascularization, Pathologic - prevention & control | Molecular Targeted Therapy - methods | Receptor, TIE-2 - antagonists & inhibitors | Angiogenesis Inhibitors - pharmacology | Niacinamide - therapeutic use | Phenylurea Compounds - therapeutic use | Neoplasms - blood supply | Piperazines - therapeutic use | Angiopoietin-1 - antagonists & inhibitors | Poly(ADP-ribose) Polymerase Inhibitors - therapeutic use | Neoplasms - drug therapy | Biomarkers, Tumor - blood | Disease-Free Survival | Phthalazines - therapeutic use | Signal Transduction - drug effects | Neovascularization, Pathologic - drug therapy | Protein Kinase Inhibitors - therapeutic use | Quinazolines - therapeutic use | Quinolines - therapeutic use | Antimitotic agents | Pancreatic cancer | Melanoma | Neovascularization | Antineoplastic agents | Vascular endothelial growth factor | Prostate cancer | Cervical cancer | Drugs | Angiogenesis | Chemotherapy | Clinical trials | Oncology | Metastasis | Cancer therapies | Tumors | Cancer
Journal Article
Journal of clinical oncology, ISSN 1527-7755, 2015, Volume 33, Issue 2, pp. 172 - 179
Purpose This open-label phase III trial evaluated efficacy and tolerability of linifanib versus sorafenib in patients with advanced hepatocellular carcinoma... 
ANGIOGENESIS | ONCOLOGY | PATHWAY | SUNITINIB | ABT-869 | RISK | BRIVANIB | INHIBITOR | CANCER | EXPRESSION | ENDOTHELIAL GROWTH-FACTOR | Niacinamide - analogs & derivatives | Humans | Middle Aged | Male | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Hand-Foot Syndrome - etiology | Indazoles - administration & dosage | Protein Kinase Inhibitors - adverse effects | Liver Neoplasms - etiology | Carcinoma, Hepatocellular - drug therapy | Antineoplastic Agents - adverse effects | Phenylurea Compounds - adverse effects | Hypertension - chemically induced | Aged, 80 and over | Receptor Protein-Tyrosine Kinases - antagonists & inhibitors | Adult | Female | Liver Neoplasms - pathology | Carcinoma, Hepatocellular - etiology | Odds Ratio | Drug Administration Schedule | Risk Factors | Kaplan-Meier Estimate | Liver Neoplasms - drug therapy | Niacinamide - adverse effects | Niacinamide - therapeutic use | Phenylurea Compounds - therapeutic use | Treatment Outcome | Niacinamide - administration & dosage | Protein Kinase Inhibitors - administration & dosage | Phenylurea Compounds - administration & dosage | Protein Kinase Inhibitors - therapeutic use | Sorafenib | Carcinoma, Hepatocellular - pathology | Aged | Indazoles - adverse effects | Indazoles - therapeutic use | Bone3 | ORIGINAL REPORTS | Bios3
Journal Article